| Autor: |
van der Weide, Hessel, Cossío, Unai, Gracia, Raquel, te Welscher, Yvonne M., ten Kate, Marian T., van der Meijden, Aart, Marradi, Marco, Ritsema, Jeffrey A. S., Vermeulen-de Jongh, Denise M. C., Storm, Gert, Goessens, Wil H. F., Loinaz, Iraida, van Nostrum, Cornelus F., Llop, Jordi, Hays, John P., Bakker-Woudenberg, Irma A. J. M. |
| Zdroj: |
Antimicrobial Agents and Chemotherapy; July 2020, Vol. 64 Issue: 9 |
| Abstrakt: |
Antimicrobial peptides (AMPs) have seen limited clinical use as antimicrobial agents, largely due to issues relating to toxicity, short biological half-life, and lack of efficacy against Gram-negative bacteria. However, the development of novel AMP-nanomedicines, i.e., AMPs entrapped in nanoparticles, has the potential to ameliorate these clinical problems. The authors investigated two novel nanomedicines based on AA139, an AMP currently in development for the treatment of multidrug-resistant Gram-negative infections. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
